APLS
NASDAQ · Biotechnology
Apellis Pharmaceuticals Inc
$41.03
+0.02 (+0.05%)
Performance
1D
—
1W
—
1M
—
3M
+79.72%
6M
+110.30%
1Y
+134.19%
YTD
+58.66%
Open$41.02
Previous Close$41.01
Day High$41.05
Day Low$41.00
52W High$41.14
52W Low$16.10
Volume—
Avg Volume3.36M
Market Cap5.25B
P/E Ratio234.62
EPS$0.12
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$23.47
Above
SMA 200
$22.25
Above
RSI (14)
47.9
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Hold
27 analysts
Price Target
-45.1% upside
Current
$41.03
$41.03
Target
$22.54
$22.54
$12.93
$22.54 avg
$29.12
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.02B | 3.03B | 2.81B |
| Net Income | 22.72M | 93.04M | 81.85M |
| Profit Margin | 2.2% | 3.1% | 2.9% |
| EBITDA | 57.70M | 115.17M | 115.66M |
| Free Cash Flow | — | 42.87M | 48.47M |
| Rev Growth | +137.0% | +21.3% | +20.6% |
| Debt/Equity | 1.23 | 0.57 | 0.45 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |